Research trends on anti-PD-1/PD-L1 immunotherapy for esophageal cancer: A bibliometric analysis

被引:0
作者
Yang, Yuanyuan [1 ]
Wang, Feng [1 ]
机构
[1] Zhengzhou Univ, Dept Oncol, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 12卷
关键词
bibliometrics; anti-PD-1; PD-L1; immunotherapy; esophageal cancer; CiteSpace; HistCite; VOSviewer; Web of Science (WOS); SQUAMOUS-CELL CARCINOMA; TUMOR MUTATIONAL BURDEN; PD-L1; EXPRESSION; EMERGING TRENDS; SAFETY; CHEMOTHERAPY; INHIBITOR; NIVOLUMAB; PEMBROLIZUMAB; BIOMARKERS;
D O I
10.3389/fonc.2022.983892
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
ObjectivesThe study aims to summarize publication characteristics of anti-programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immunotherapy for esophageal cancer and create scientific maps to explore hotspots and emerging trends with bibliometric methods. MethodsThe publications between 2012 and 2021 were retrieved from the Web of Science Core Collection (WoSCC) on June 20, 2022. Bibliometric tools including HistCite, VOSviewer, and CiteSpace were used for statistical analysis. Data on the trend of the annual output, countries/regions, institutions, journals, authors, subject categories, keywords, and co-cited references were presented in this study. ResultsA total of 552 publications written by 3,623 authors of 872 institutions, 44 countries/regions in 250 journals were included in the bibliometric study. China, USA and Japan were the key countries in this field. Kato Ken, Bang Yung-Jue, Frontiers in Oncology, Journal of Clinical Oncology and Natl Canc Ctr were the top 1 productive author, co-cited author, productive journal, co-cited journal and prolific institution, respectively. The top 4 most present keywords were esophageal cancer, immunotherapy, esophageal squamous cell carcinoma and PD-L1. Neoadjuvant chemotherapy, response, PD-1 blockade and CD8(+) T cell were four latest research frontiers. The keywords reflected the progress from PD-1/PD-L1 expression to the clinical application of PD-1/PD-L1 inhibitors. The current researches mainly focus on neoadjuvant immunotherapy for esophageal cancer and development of biomarkers. Further research is warranted to determine effective predictive biomarkers or models, illustrate the molecular mechanism of combined treatment, and construct the optimal therapeutic strategy. ConclusionsThis study visually analyzed the global trend and hotspots of anti-PD-1/PD-L1 immunotherapy for esophageal cancer over the past decade. The results could guide scientists to comprehensively understand the global frontiers and determine future directions.
引用
收藏
页数:14
相关论文
共 74 条
  • [1] The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma
    Akutsu, Yasunori
    Murakami, Kentaro
    Kano, Masayuki
    Toyozumi, Takeshi
    Matsumoto, Yasunori
    Takahashi, Masahiko
    Otsuka, Ryota
    Sekino, Nobufumi
    Yokoyama, Masaya
    Shiraishi, Tadashi
    Matsubara, Hisahiro
    [J]. ESOPHAGUS, 2018, 15 (02) : 103 - 108
  • [2] Immunotherapy of Esophageal Cancer: Current Status, Many Trials and Innovative Strategies
    Alsina, Maria
    Moehler, Markus
    Lorenzen, Sylvie
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 (05) : 266 - 271
  • [3] A Bibliometric Analysis of International Publication Trends in Total Temporomandibular Joint Replacement Research (1986-2020)
    Balel, Yunus
    Tumer, Mehmet Kemal
    [J]. JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY, 2021, 79 (07) : 1458.e1 - 1458.e12
  • [4] Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    Bang, Yung-Jue
    Van Cutsem, Eric
    Feyereislova, Andrea
    Chung, Hyun C.
    Shen, Lin
    Sawaki, Akira
    Lordick, Florian
    Ohtsu, Atsushi
    Omuro, Yasushi
    Satoh, Taroh
    Aprile, Giuseppe
    Kulikov, Evgeny
    Hill, Julie
    Lehle, Michaela
    Ruschoff, Josef
    Kang, Yoon-Koo
    [J]. LANCET, 2010, 376 (9742) : 687 - 697
  • [5] Microsatellite Instability: A Predictive Biomarker for Cancer Immunotherapy
    Chang, Liisa
    Chang, Minna
    Chang, Hanna M.
    Chang, Fuju
    [J]. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2018, 26 (02) : E15 - E21
  • [6] Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014)
    Chen, Chaomei
    Dubin, Rachael
    Kim, Meen Chul
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2014, 14 (09) : 1295 - 1317
  • [7] CiteSpace II: Detecting and visualizing emerging trends and transient patterns in scientific literature
    Chen, CM
    [J]. JOURNAL OF THE AMERICAN SOCIETY FOR INFORMATION SCIENCE AND TECHNOLOGY, 2006, 57 (03): : 359 - 377
  • [8] Searching for intellectual turning points: Progressive knowledge domain visualization
    Chen, CM
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 : 5303 - 5310
  • [9] Mapping Trends in Moyamoya Angiopathy Research: A 10-Year Bibliometric and Visualization-Based Analyses of the Web of Science Core Collection (WoSCC)
    Chen, Danyang
    Zhang, Ge
    Wang, Jiahui
    Chen, Shiling
    Wang, Jingxuan
    Nie, Hao
    Tang, Zhouping
    [J]. FRONTIERS IN NEUROLOGY, 2021, 12
  • [10] Perioperative Outcomes of Minimally Invasive Esophagectomy After Neoadjuvant Immunotherapy for Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
    Cheng, Jiahan
    Guo, Minzhang
    Yang, Yushang
    Liu, Yilin
    Hu, Weipeng
    Shang, Qixin
    Li, Chuan
    Xia, Liang
    Wang, Yun
    Wang, Wenping
    Tian, Dong
    Yuan, Yong
    Hu, Yang
    Chen, Longqi
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13